Form 4: CalciMedica Interim CFO Acquires Warrants
SEC Form 4 Filing
Daniel E. Geffken, Interim CFO of CalciMedica, Inc., reports the acquisition of warrants exercisable for 10,000 shares of common stock.
Summary
- On May 17, 2024, Daniel E. Geffken, the Interim CFO of CalciMedica, Inc., acquired warrants for 10,000 shares of common stock.
- The warrants have an exercise price of $5.45.
- The warrants vest and become exercisable in twelve equal monthly installments starting May 17, 2024.
- The warrants expire on May 16, 2034.
- The warrants are indirectly owned by SG Dan Equity Holdings, LLC.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard regulatory filing reporting an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure of insider activity, which is common in the pharmaceutical industry. It provides transparency into the holdings of company executives.
Stakeholder Impact
- The acquisition of warrants by an executive could be viewed positively by shareholders as it aligns management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of warrant acquisition and start of vesting period. |
| 05/16/2034 | Expiration date of the warrants. |
| 05/20/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.